ReviewNature reviews. Clinical oncology2009
Systems pathology--taking molecular pathology into a new dimension.
Review in Nature reviews. Clinical oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Article
- Elevated Neutrophil-to-Lymphocyte Ratio in Perioperative Periods is Suggestive of Poor Prognosis in Patients with Colorectal Cancer.Journal of inflammation research · 2021Article
- Article
- Novel Monte Carlo approach quantifies data assemblage utility and reveals power of integrating molecular and clinical information for cancer prognosis.Scientific reports · 2015Article
- Dynamic contrast-enhanced MRI evaluates the early response of human head and neck tumor xenografts following anti-EMMPRIN therapy with cisplatin or irradiation.Journal of magnetic resonance imaging : JMRI · 2015Article
- Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.The Journal of pathology · 2014Review
- Advanced systems biology methods in drug discovery and translational biomedicine.BioMed research international · 2013Review
- Open biomedical pluralism: formalising knowledge about breast cancer phenotypes.Journal of biomedical semantics · 2012Article
- Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2012Article
- Article
- Systems pathology: a critical review.Molecular oncology · 2012Review
- What can molecular pathology contribute to the management of renal cell carcinoma?Nature reviews. Urology · 2011Review
- Systems pathology.Breast cancer research : BCR · 2010Article
- Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations.Molecular cancer therapeutics · 2010Review
- The cycling hair follicle as an ideal systems biology research model.Experimental dermatology · 2010Article
- Would Virchow be a systems biologist? A discourse on the philosophy of science with implications for pathological research.Virchows Archiv : an international journal of pathology · 2010Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The wealth of morphological, histological, and molecular data from human cancers available to pathologists means that pathology is poised to become a truly quantitative systems science. By measuring morphological parameters such as tumor stage and grade, and by measuring molecular biomarkers such as hormone receptor status, pathologists have sometimes accurately predicted what will happen to a patient's tumor. While 'omic' technologies have seemingly improved prognostication and prediction, some molecular 'signatures' are not useful in clinical practice because of the failure to independently validate these approaches. Many associations between gene 'signatures' and clinical response are correlative rather than mechanistic, and such associations are poor predictors of how cellular biochemical networks will behave in perturbed, diseased cells. Using systems biology, the dynamics of reactions in cells and the behavior between cells can be integrated into models of cancer. The challenge is how to integrate multiple data from the clinic into tractable models using mathematical models and systems biology, and how to make the resultant model sufficiently robust to be of practical use. We discuss the difficulties in using mathematics to model cancer, and review some approaches that may be used to allow systems biology to be successfully applied in the clinic.
Indexed as
Identifiers
19581910What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.